arrow
A

Alexander Guminski

faculty of medicine and health
H指数:45
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours

疫苗诱导的免疫在胶质瘤患者中维持,与其他实体瘤相比。

2025-10-150
OA
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWERCSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6
2025-01-013
PRE
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)
2024-06-012
PRE
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

延长cemiplimab剂量治疗晚期皮肤鳞状细胞癌的高反应率

2024-03-111
OAAI
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study
2024-01-115
OAAI
PHARMACOKINETIC AND IMMUNOLOGIC DATA FROM A PHASE I STUDY OF THE CLICK CHEMISTRY-BASED THERAPY SQ3370 IN ADVANCED SOLID TUMORS AND SOFT-TISSUE SARCOMA PROVIDES PROOF-OF-CONCEPT FOR THE CAPAC PLATFORM
2021-11-100
OA
Nivolumab (N) plus ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651
2021-09-0124
OAAI
Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition
2021-08-2511
OAAI
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

cemiplimab治疗晚期皮肤鳞状细胞癌2期研究的综合分析: 延长随访结果和生活质量分析

2021-08-1960
OAAI
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma

III期黑色素瘤新辅助免疫治疗后的病理反应和肿瘤床组织病理学特征与生存率相关

2021-06-0128
OAAI
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
2020-10-0130
OAAI
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
2020-06-17118
OAAI